STOCK TITAN

MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

MAIA Biotechnology (MAIA) reported updated interim efficacy data for ateganosine in its Phase 2 THIO-101 expansion trial in advanced non-small cell lung cancer.

Across Parts A, B and C, disease control was 88% (38 of 43 patients) as of October 01, 2026, among third-line patients evaluable for efficacy who had at least one tumor scan after starting treatment. Disease control means stable disease or better. Patients had progressed after prior immunotherapy and chemotherapy. Reported disease control for standard third-line chemotherapy regimens was 25%–35%; this is a historical comparison.

Part C enrollment is complete. Ateganosine has FDA Fast Track designation, and MAIA said further Part C data may support an accelerated approval filing. The ongoing pivotal Phase 3 THIO-104 trial targets the same population, with an interim survival analysis planned for 2027.

Loading...
Loading translation...
5 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointDisease control reached 88% (38 of 43 patients) across THIO-101 Parts A–C, versus historical chemotherapy reports of 25%–35%.
  • Minor pointPart C enrollment is complete in the Phase 2 THIO-101 expansion trial.
  • Minor pointFDA Fast Track designation applies to ateganosine’s development.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Further Part C data may support an accelerated approval filing, MAIA said.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pivotal Phase 3 THIO-104 is ongoing, with an interim survival analysis planned for 2027.

Negative

  • Minor pointInterim efficacy results cover only 43 evaluable patients with at least one post-treatment tumor scan.

Key Figures

Disease control rate: 88% (38 of 43 patients) Standard chemotherapy disease control: 25%–35% Interim survival analysis: 2027 +1 more
Disease control rate
88% (38 of 43 patients)
Parts A, B and C; as of October 1, 2026; efficacy-evaluable patients with at least one post-treatment tumor scan
Standard chemotherapy disease control
25%–35%
Reported range for standard third-line chemotherapy regimens
Interim survival analysis
2027
THIO-104 Phase 3 trial milestone
Ateganosine dose
180 mg
Followed by cemiplimab in 21-day cycles

Previous Clinical trial Reports

2 past events · Latest: Oct 07
Same Type 2 events
  1. Oct 07

    Phase 2 efficacy data

    24h Move
    -0.8%

    THIO-101 enrollment was complete and the company reported interim disease control data.

  2. Jul 08

    Phase 2 efficacy data

    24h Move
    +0.0%

    Initial Part C results reported disease control with ateganosine followed by cemiplimab.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

disease control rate, overall survival, pd-(l)1 inhibition, fast track designation, +1 more
5 terms
disease control rate medical
"the observed disease control rate (DCR) for third-line NSCLC patients"
The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.
overall survival medical
"DCR serves as an excellent data surrogate for Overall Survival (OS) efficacy"
Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.
pd-(l)1 inhibition medical
"ateganosine followed by PD-(L)1 inhibition"
PD-(L)1 inhibition is a type of cancer immunotherapy that blocks the interaction between the immune checkpoint receptor PD-1 (on T cells) and its ligand PD-L1 (on tumor or other cells). By preventing that binding, these drugs remove a brake on T cells and can restore or increase their ability to recognize and kill cancer cells. The approach typically uses monoclonal antibodies or similar agents and can produce immune-driven inflammation in normal tissues, so its effectiveness and side effects depend on the tumor's biology and the patient's immune state.
fast track designation regulatory
"under FDA’s Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
accelerated approval regulatory
"may support accelerated approval filing with FDA"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MAIA advances novel telomere-targeting agent under FDA’s Fast Track designation

Further data from THIO-101 Part C may support accelerated approval filing with FDA

CHICAGO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). THIO-101 Part C is evaluating additional patients to confirm the strong efficacy data observed in Parts A and B of the study. 

The Phase 2 trial assesses advanced NSCLC patients who were nonresponsive or developed resistance and progressed after prior immune checkpoint inhibitor therapy and chemotherapy. Patients are treated with ateganosine 180mg followed by cemiplimab (Libtayo®) in cycles of 21 days. The sequential administration of ateganosine followed by PD-(L)1 inhibition is intended to enhance and prolong the antitumor immune response.

“It is encouraging to see an 88% disease control rate (DCR) as the THIO-101 data continue to mature. DCR serves as an excellent data surrogate for Overall Survival (OS) efficacy according to a historical meta-analysis1 and our own analysis of previous data,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, the trial’s combined study data have consistently demonstrated stable disease or better at the first tumor assessment following treatment initiation. Importantly, the Part C interim efficacy results are well aligned with the outcomes observed in Parts A and B, now across a substantially larger patient population. Consistency of the results as our patient pool expands further strengthens the compelling efficacy signals we are seeing for both of our trials in NSCLC.”

For Parts A, B, and C of THIO-101 as of October 01, 2026, the observed disease control rate (DCR) for third-line NSCLC patients resistant to chemo and immunotherapy is 88% (38 of 43 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment. This DCR measure contrasts with reported 25%–35% disease control for standard 3L chemotherapy regimens.1

MAIA has completed enrollment in Part C of its Phase 2 THIO-101 expansion, which enrolled patients in Hungary, Poland, Turkey, Georgia, Romania, Taiwan, and in the United States. Concurrently, an ongoing pivotal Phase 3 clinical trial of third line ateganosine treatment, THIO-104, with the same target population as THIO-101 Part C, is advancing toward regulatory milestones including 2027 interim survival analysis.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com


1 Matsumoto H, et al. Transl Lung Cancer Res 2021;10:2278–89


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MAIA’s THIO-101 trial show for lung cancer disease control?

THIO-101 Parts A, B and C showed 88% disease control (38 of 43 patients) as of October 01, 2026. The efficacy-evaluable population comprised third-line non-small cell lung cancer patients resistant to chemotherapy and immunotherapy who had at least one tumor scan after starting treatment.

How is ateganosine administered in MAIA’s THIO-101 trial?

Patients receive ateganosine 180mg followed by cemiplimab (Libtayo) in cycles of 21 days. The trial evaluates advanced non-small cell lung cancer patients who were nonresponsive or developed resistance and progressed after prior immune checkpoint inhibitor therapy and chemotherapy.

Keep reading